Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 2 2

Status

Withdrawn 1Unknown 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 4Head & Neck 2Genitourinary 2Gastrointestinal 2Sarcoma 1Other solid neoplasm 1Gynecologic 1Breast 1

Conditions

Urinary Bladder Neoplasms 1Castration Resistant Prostate Cancer 1Carcinoma, Transitional Cell 1

Interventions

Docetaxel 191Gemcitabine 148Prednisone 142pembrolizumab 125enzalutamide 119Abiraterone Acetate 108Nivolumab 107Cisplatin 103Magnetic Resonance Spectroscopy 100Radiotherapy 95Sunitinib 94Leuprolide 91Carboplatin 82Specimen Handling 71Androgen Antagonists 63bicalutamide 60Radiosurgery 60Paclitaxel 59Goserelin 59Ipilimumab 57Bevacizumab 57apalutamide 53Sorafenib 53acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 51Everolimus 49cabozantinib 48abiraterone 46atezolizumab 45cabazitaxel 43durvalumab 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × bintrafusp alfa protein, human × Genitourinary × Clear all
NCT05445882 2024-04-02

N-803 Alone or in Combination With BN-Brachyury Vaccine or Bintrafusp Alfa (M7824) for Participants With Castration Resistant Prostate Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Withdrawn
Genitourinary

Castration Resistant Prostate Cancer

NCT04878250 2021-05-07

PEBBLE

Queen Mary University of London

Phase 2 Unknown
49 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡